Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of GSK4771261 Administered as a Single Subcutaneous Dose to Healthy Participants of Chinese, Japanese and White/European Ancestry Aged 25 to 55 Years of Age Inclusive

NCT07600450 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07600450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07600450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of GSK4771261 Administered as a Single Subcutaneous Dose to Healthy Participants of Chinese, Japanese and White/European Ancestry Aged 25 to 55 Years of Age Inclusive
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Recruiting
Start date
May 18, 2026
Completion date
May 20, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney disease